🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 38 Shanghai 34 Beijing 24 Chengdu 13 Wuhan 11
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Shanghai Chest Hospital9 Shanghai Pulmonary Hospital, Shanghai, China8 Fudan University3 AstraZeneca2 Intuitive Surgical1
Site location
Guangzhou38 Shanghai34 Beijing24 Chengdu13 Wuhan11
All 49 locations
Target enrolment
to

Trials with a site in Shanghai

34 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
5G-Enabled Remote Robotic-Assisted Bronchoscopy-Guided Cryoablation for Pulmonary Malignancies
NCT07830095Lung Cancer
Shanghai Chest Hospital
Not applicable
15
Shanghai
2026-09-30
Recruiting
TROP2 NMR Concordance Study
NCT07624318Lung Cancer
AstraZeneca
Observational
3,400
Beijing, Guangzhou, Shanghai
2026-08-13
Recruiting
Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
NCT07681245Lung Cancer
Shanghai Chest Hospital
Observational
294
Shanghai
2026-07-03
Recruiting
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
NCT07593248Lung Cancer
AstraZeneca
Observational
2,000
Beijing, Chengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang
2026-06-22
Recruiting
Association Between Screening Behaviors and Lung Cancer Spectrum
NCT07626177Lung Cancer
Fudan University
Observational
5,390
Shanghai
2026-05-14
Not yet open
A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
NCT07014878Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Beijing DCTY Biotech Co.,Ltd.
Phase 1
18
Shanghai
2026-05
Recruiting
Olive Oil Before Lung Cancer Surgery to Prevent Chylothorax
NCT07807696Lung Cancer, Chylothorax
Fudan University
Not applicable
1,036
Shanghai
2026-03-15
Not yet open
A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study
NCT07375979Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
14,300
Shijiazhuang, Zhengzhou, Changchun, Shenyang, Shanghai, Kunming
2026-02-05
Recruiting
A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT07232849Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
100
Shanghai, Hangzhou
2025-12-04
Recruiting
Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study
NCT07243873Lung Cancer, PET-CT
Shanghai Pulmonary Hospital, Shanghai, China
Observational
10,000
Zunyi, Jiangxi, Shanghai, Ningbo
2025-12-01
Recruiting
Safety and Efficacy Evaluation of Cryoablation in the Treatment of Ground-Glass Nodules
NCT07232433Lung Cancer
Ruijin Hospital
Not applicable
90
Shanghai
2025-11-21
Recruiting
Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine
NCT07134660Postoperative Pain, Acute, Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
210
Shanghai
2025-09-01
Recruiting
Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC
NCT07135856Lung Cancer, Neoadjuvant Therapy
Shanghai Chest Hospital
Observational
400
Shanghai
2025-09-01
Not yet open
A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy
NCT07101627Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
149
Nanjing, Shanghai
2025-08-01
Recruiting
Transbronchial MWA for Pulmonary Tumors
NCT06969014Lung Cancer
Shanghai Chest Hospital
Not applicable
15
Shanghai
2025-05-12
Not yet open
Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC
NCT06688656Lung Cancer
Shanghai Chest Hospital
Phase 2
30
Shanghai
2025-03-31
Recruiting
Biomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer
NCT06818149Lung Cancer, Myocarditis Due to Drug
Shanghai Chest Hospital
Observational
50
Shanghai
2025-01-30
Recruiting
Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer
NCT07026110Lung Cancer, Lung Diseases, Lung Neoplasms, Lung Cancer Metastatic
RenJi Hospital
Not applicable
100
Shanghai
2024-12-23
Recruiting
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
NCT06749886Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
22
Shanghai
2024-11-19
Recruiting
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
NCT07433283Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer
Sichuan Enray Pharmaceutical Sciences Company
Phase 1/2
54
Beijing, Hunan, Chongqing, Fuzhou, Haikou, Heilongjiang, Shanghai, Chengdu
2024-11-12
Active, closed
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT06644768Non-small Cell Lung Cancer, Lung Cancer
Daiichi Sankyo
Phase 1/2
137
Changchun, Hangzhou, Harbin, Jiamusi, Shanghai, Tiyuan, Zhengzhou
2024-10-30
Recruiting
Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
NCT06572540Lung Cancer
Jiayuan Sun
Not applicable
110
Guangzhou, Zhengzhou, Shanghai, Chengdu, Hangzhou
2024-09-01
Recruiting
Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
NCT06518655Pulmonary Nodules, Multiple, Pulmonary Nodules, Solitary, Lung Cancer
ChromX Health
Observational
3,000
Beijing, Foshan, Guangzhou, Wuhan, Shanghai, Chengdu
2024-06-30
Not yet open
Efficacy and Safety of Multimode Thermal Therapy in the Treatment of Early Peripheral Lung Cancer
NCT06453889Lung Cancer
Shanghai Chest Hospital
Not applicable
10
Shanghai
2024-06-05
Recruiting
Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
NCT06483295Lung Cancer
Shanghai Chest Hospital
Not applicable
216
Shanghai
2024-03-24
Active, closed
A Trial to Compare Robotic Assisted Bronchoscopy Ion's Clinical Utility for Peripheral Lung Nodule Access and Diagnosis to ENB
NCT06308120Pulmonary Nodule, Solitary, Lung Cancer
Intuitive Surgical
Not applicable
354
Shanghai, Chengdu
2024-03-20
Recruiting
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
NCT06749860Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
58
Shanghai
2024-02-02
Recruiting
Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study
NCT06216782Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
2,000
Shanghai
2023-12-16
Not yet open
Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
NCT06102161Lung Cancer, Wedge Resection, Ground-glass Opacity
Fudan University
Phase 3
286
Shanghai
2023-11
Recruiting
Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
NCT05965557Lung Cancer
Geneplus-Beijing Co. Ltd.
Observational
100
Shanghai
2023-06-19
Recruiting
Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment
NCT05857800Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
2,000
Shanghai
2023-05-25
Recruiting
Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors
NCT05834413Lung Cancer
Shanghai University of Traditional Chinese Medicine
Not applicable
367
Shanghai
2023-05-01
Recruiting
China Lung Cancer Screening (CLUS) Study Version 3.0
NCT05494021Lung Cancer
Shanghai Chest Hospital
Not applicable
100,000
Shanghai
2022-01-01
Recruiting
Integrative Analysis of Large-cell Lung Cancer
NCT02917369Lung Cancer
Shanghai 10th People's Hospital
Observational
1,000
Ganzhou, Shanghai
2016-01
Rows per page Showing 1–34 of 34
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 34 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

25 of the 34 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 7 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 34 studies
PhaseStudiesRecruitingShare
Observational131238.2%
Not applicable12935.3%
Phase 25314.7%
Phase 1/2215.9%
Phase 1102.9%
Phase 3102.9%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Shanghai Chest Hospital96
Shanghai Pulmonary Hospital, Shanghai, China86
Fudan University32
AstraZeneca22
Beijing DCTY Biotech Co.,Ltd.10
ChromX Health11
Daiichi Sankyo10
Geneplus-Beijing Co. Ltd.11
Intuitive Surgical10
Jiangsu HengRui Medicine Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.